Clinical Response to Treatment with Teriparatide in an Adolescent with Osteoporosis-Pseudoglioma Syndrome (OPPG): A Case Report.

IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM
International Journal of Endocrinology and Metabolism Pub Date : 2022-04-27 eCollection Date: 2022-04-01 DOI:10.5812/ijem-121031
Ali Homaei, Victoria Chegini, Fatemeh Saffari
{"title":"Clinical Response to Treatment with Teriparatide in an Adolescent with Osteoporosis-Pseudoglioma Syndrome (OPPG): A Case Report.","authors":"Ali Homaei,&nbsp;Victoria Chegini,&nbsp;Fatemeh Saffari","doi":"10.5812/ijem-121031","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Osteoporosis-pseudoglioma syndrome (OPPG) is a rare autosomal recessive disorder characterized by severe osteoporosis and eye abnormalities that leads to vision loss. In this study, we report the outcome of a short period of treatment with teriparatide in one patient with OPPG.</p><p><strong>Case presentation: </strong>The patient was a 17-year-old girl who suffered a bone fracture at the age of two and was diagnosed with OPPG at the age of three. Genetic testing was performed for the patient, and a novel homozygous nonsense mutation (c.351G>A) in exon 2 of the LRP5 gene was reported. She was treated with pamidronate, but the bone fracture increased, and the disability progressed. Therefore, at the age of 11 years and nine months, teriparatide was administered subcutaneously at a dose of 20 micrograms per day for four consecutive months. After the treatment with teriparatide, physical activity was achieved, and no further fractures were observed besides the gradual rise in bone mineral density (BMD) (from 0.532 to 0.711 gr/cm<sup>2</sup> in lumbar spine and 0.372 to 0.635 gr/cm<sup>2</sup> in femur neck).</p><p><strong>Conclusions: </strong>In children and adolescents diagnosed with OPPG who do not respond to other conventional therapies, short courses of teriparatide therapy may be helpful.</p>","PeriodicalId":13969,"journal":{"name":"International Journal of Endocrinology and Metabolism","volume":"20 2","pages":"e121031"},"PeriodicalIF":2.1000,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/42/ijem-20-2-121031.PMC9383542.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/ijem-121031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/4/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 4

Abstract

Introduction: Osteoporosis-pseudoglioma syndrome (OPPG) is a rare autosomal recessive disorder characterized by severe osteoporosis and eye abnormalities that leads to vision loss. In this study, we report the outcome of a short period of treatment with teriparatide in one patient with OPPG.

Case presentation: The patient was a 17-year-old girl who suffered a bone fracture at the age of two and was diagnosed with OPPG at the age of three. Genetic testing was performed for the patient, and a novel homozygous nonsense mutation (c.351G>A) in exon 2 of the LRP5 gene was reported. She was treated with pamidronate, but the bone fracture increased, and the disability progressed. Therefore, at the age of 11 years and nine months, teriparatide was administered subcutaneously at a dose of 20 micrograms per day for four consecutive months. After the treatment with teriparatide, physical activity was achieved, and no further fractures were observed besides the gradual rise in bone mineral density (BMD) (from 0.532 to 0.711 gr/cm2 in lumbar spine and 0.372 to 0.635 gr/cm2 in femur neck).

Conclusions: In children and adolescents diagnosed with OPPG who do not respond to other conventional therapies, short courses of teriparatide therapy may be helpful.

Abstract Image

Abstract Image

特立帕肽治疗青少年骨质疏松-假性胶质瘤综合征(OPPG)的临床反应:1例报告。
骨质疏松-假性胶质瘤综合征(osteoporosis -pseudoglioma syndrome, OPPG)是一种罕见的常染色体隐性遗传病,其特征是严重骨质疏松和眼睛异常,导致视力丧失。在这项研究中,我们报告了一名OPPG患者短期使用特立帕肽治疗的结果。病例介绍:患者是一名17岁的女孩,她在2岁时骨折,3岁时被诊断为OPPG。对患者进行了基因检测,报告了LRP5基因外显子2的新型纯合无义突变(c.351G> a)。她接受帕米膦酸盐治疗,但骨折增加,残疾进展。因此,在11岁零9个月时,以每天20微克的剂量皮下注射特立帕肽,连续4个月。经特立帕肽治疗后,患者恢复体力活动,除骨密度(BMD)逐渐升高(腰椎从0.532至0.711 gr/cm2,股骨颈从0.372至0.635 gr/cm2)外,未见进一步骨折。结论:对于诊断为OPPG的儿童和青少年,如果对其他常规治疗没有反应,短期的特立帕肽治疗可能会有所帮助。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
4.80%
发文量
0
期刊介绍: The aim of the International Journal of Endocrinology and Metabolism (IJEM) is to increase knowledge, stimulate research in the field of endocrinology, and promote better management of patients with endocrinological disorders. To achieve this goal, the journal publishes original research papers on human, animal and cell culture studies relevant to endocrinology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信